Open Nav

Please submit your session questions in advance at

Brainstorm Cell Therapeutics

  • Chaim Lebovits, Brainstorm Cell Therapeutics

BrainStorm Cell Therapeutics Inc. is a leading cellular therapy biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. BrainStorm holds the rights to clinical development and commercialization of the NurOwn® technology platform through an exclusive, worldwide licensing agreement. NurOwn® has received Fast Track designation from the U.S. Food and Drug Administration (U.S. FDA) in ALS and has additionally been granted Orphan Status by the U.S. FDA and the European Medicines Agency (EMA).

  • Date:Monday, February 11
  • Time:10:15 AM - 10:30 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Submission ID:23250
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Attract Investors
  • Company
  • Company HQ City:New York
  • Company HQ State:New York
  • Company HQ Country:United States
  • Ticker:BCLI
  • Exchange:NASDAQ
  • CEO/Top Company Official:ChaimLebovits
  • Year Founded:2004
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development:NurOwn(R)
  • Development Phase of Primary Product:Phase III
Chaim Lebovits
Brainstorm Cell Therapeutics